In a report released today, Serge Belanger from Needham maintained a Buy rating on Oculis Holding, with a price target of $40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Serge Belanger has given his Buy rating due to a combination of factors that emerged from Oculis Holding’s participation at the Needham Healthcare Conference. His positive stance appears driven by the strategic visibility the company gained with investors through its presentation and fireside chat, reinforcing confidence in management’s ability to communicate and execute its vision.
Belanger likely views Oculis’s presence at a high‑profile industry event as a sign of ongoing engagement with the capital markets and potential catalysts ahead. The continued inclusion of Oculis in Needham’s healthcare programming suggests sustained interest in the company’s story, supporting his conviction that the stock offers attractive upside for investors at current levels.
According to TipRanks, Belanger is a 5-star analyst with an average return of 10.6% and a 48.00% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Esperion, and Cormedix.